William Blair Has Strong Estimate for AWH FY2024 Earnings

Aspira Women’s Health Inc. (NASDAQ:AWH) – Equities research analysts at William Blair lifted their FY2024 earnings per share estimates for shares of Aspira Women’s Health in a report issued on Tuesday, November 26th. William Blair analyst A. Brackmann now forecasts that the company will post earnings of ($1.07) per share for the year, up from their previous estimate of ($1.19). The consensus estimate for Aspira Women’s Health’s current full-year earnings is ($1.26) per share. William Blair also issued estimates for Aspira Women’s Health’s Q4 2024 earnings at ($0.21) EPS, Q1 2025 earnings at ($0.17) EPS, Q2 2025 earnings at ($0.16) EPS, Q3 2025 earnings at ($0.13) EPS, Q4 2025 earnings at ($0.12) EPS and FY2025 earnings at ($0.57) EPS.

A number of other equities analysts have also recently issued reports on the company. Alliance Global Partners lowered their target price on Aspira Women’s Health from $7.00 to $5.50 and set a “buy” rating for the company in a report on Wednesday, August 14th. StockNews.com initiated coverage on Aspira Women’s Health in a report on Monday. They set a “hold” rating for the company.

Aspira Women’s Health Stock Up 6.6 %

Shares of AWH stock opened at $0.81 on Thursday. Aspira Women’s Health has a 12-month low of $0.67 and a 12-month high of $5.65. The firm has a fifty day moving average of $0.83 and a 200-day moving average of $1.28. The company has a market capitalization of $13.50 million, a price-to-earnings ratio of -0.67 and a beta of 1.44.

Institutional Investors Weigh In On Aspira Women’s Health

A hedge fund recently bought a new stake in Aspira Women’s Health stock. Pine Valley Investments Ltd Liability Co purchased a new position in shares of Aspira Women’s Health Inc. (NASDAQ:AWH) during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 31,200 shares of the company’s stock, valued at approximately $25,000. Pine Valley Investments Ltd Liability Co owned about 0.19% of Aspira Women’s Health as of its most recent SEC filing. Institutional investors own 12.19% of the company’s stock.

About Aspira Women’s Health

Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.